December 05, 2023
1 min watch
Save
VIDEO: Cellular immunotherapy for sarcoma ‘potential option in the future’
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Sandra D’Angelo, MD, talked about a study examining the role of tumor-infiltrating lymphocyte, or TIL, in metastatic sarcoma presented at the Connective Tissue Oncology Society Annual Meeting in a video interview.
“There were no responses seen; however, this is interesting in that it holds this particular modality of adoptive cell therapy as a potential option in the future. It highlights that TIL can be manufactured for some patients with a diagnosis of sarcoma,” D’Angelo, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, told Healio.
Reference:
- Mullinax J, et al. Paper 33. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
D’Angelo reports consulting/advising for Aadi Bioscience, Adaptimmune, Amgen, EMD Serono, GI Innovations, GSK, Immune Design, Immunocore, Incyte, Merck, Nektar, Pfizer, Rain Therapeutics and Servier; research funding from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono, Incyte, Merck and Nektar; receiving travel/accommodations expenses from Adaptimmune, EMD Serono and Nektar; and being on a data safety monitoring board/advisory board for Adaptimmune, GSK, Merck and Nektar.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.